Skip to content

Safety and efficacy evaluation of polymyxin B direct hemoperfusion in idiopathic pulmonary fibrosis patients with acute exacerbation

Safety and efficacy evaluation of polymyxin B direct hemoperfusion in idiopathic pulmonary fibrosis patients with acute exacerbation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003751
Enrollment
10
Registered
2019-04-12
Start date
2021-02-20
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Among patients with acute exacerbation (sudden respiratory symptoms worsening within 1 month) of idiopathic pulmonary fibrosis and P/F ratio <300 (based on acute lung injury) within 7

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Registers the subject from the IRB passage day. Among older than 19 years IPF patients with acute exacerbations (sudden respiratory symptoms worsening within 1 month), Patients who agreed steroid pulse therapy and signed permission. 1) Selection Criteria - AE-IPF is diagnosed by the following criteria (1) Previous or current diagnosis of IPF (2) aggravation or dyspnea of unknown cause lasting less than one month (3) high-resolution computed tomography (CT) images showed peripheral usual interstitial pneumonia pattern and newly developed bilateral ground glass opacity and/or consolidation (4) deterioration not fully explained by heart failure or other fluids overload

Exclusion criteria

Exclusion criteria: 1) Pediatric patients under the age of 18 2) Failure to obtain agreement 3) In the case of other diseases affecting survival besides IPF (heart failure, cancer, etc.) 4) In addition to hypoxemia, other organ failure such as hemodynamic instability 5) Accompanying severe hemorrhagic disease 6) In cases where there is reason to exclude other opinions of the investigator 7) Older than 80 years old 8) History of hypersensitivity to dialysis or extracorporeal circulation 9) Cardiovascular disease 10) Pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
Evaluation of P / F ratio improvement;Changes for laboratory test;Survival time

Countries

Korea, Republic of

Contacts

Public ContactJin Woo Song

Asan Medical Center

skysong3@hanmail.net+82-2-3010-8532

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026